clinical trials

Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma.

Authors: Anderson SK, Brown PD, Caine C, Cerhan JH, Johnson DR, Lachance DH, Yan E

Journal: Neuro-oncology practice

Background: Cognitive function is an important outcome measure in many brain tumor clinical trials, and investigators are interested in employing the most efficient methods of cognitive assessment for this purpose. Computerized testing can be appealing because […]

The National Institute on Aging and the Alzheimer’s Association Research Framework for Alzheimer’s disease: Perspectives from the Research Roundtable.

Authors: Bain LJ, Canniere MZ, Carrillo MC, Haeberlein SB, Hendrix JA, Jack CR Jr, Kerchner G, Knopman DS, Kolb H, Margolin R, Maruff P, Mattsson N, Miller DS, Montine TJ, Murray ME, Nelson PT, Petersen RC, Resnick SM, Romano G, Sano M, Schneider JA, Siemers E, Sultzer DL, Tome MB, Tong G, van Harten AC, Vemuri P, Wolk DA

Journal: Alzheimer's and Dementia

The Alzheimer’s Association’s Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer’s Association Research Framework for Alzheimer’s disease. The meeting allowed experts in the field from academia, industry, […]

Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer’s disease.

Authors: Brodtmann A, Budge M, Darby D, Maruff P, Woodward M

Journal: International Psychogeriatrics / IPA

BACKGROUND: Ideally putative disease-modifying therapies for Alzheimer’s disease (AD) should be tested in patients who have minimal morbidity. Current barriers to such trials in early disease include the lack of disease-specific early biomarkers, insensitivity of quantitative […]

Back to Publications